Week Ending June 6, 2022

ASCO22: Lung cancer therapy could help patients live longer
“Late-breaking research from Cedars-Sinai Cancer finds an immunotherapy drug combination Improves survival for patients with immunotherapy-resistant, non-small cell lung cancer.”

Adagrasib Improves Outcomes in KRAS-Mutated NSCLC, Phase II Study Shows
“Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of the KRYSTAL-1 trial presented by Spira et al at the 2022 ASCO Annual Meeting (Abstract 9002). The findings were simultaneously published in The New England Journal of Medicine.”

Lung Cancer Mutation Consortium Sites Initiate LEADER Trial
“The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the initiation of trial sites at USC Norris Cancer Center, University of California-Davis, University of Michigan, and University of Washington for its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.”

Shared decision-making required when choosing first-line regimen for PD-L1-high NSCLC
CHICAGO — “Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small-cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.”

Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost
— Phase II trial sees “synergistic benefit” with checkpoint blockade and anti-angiogenesis
CHICAGO – “Randomized data suggest that an anti-angiogenic agent can kick-start immunotherapy’s antitumor activity in non-small cell lung cancer (NSCLC) patients whose disease has already progressed after chemotherapy and a checkpoint inhibitor.”

COSMIC-021 points to cabozantinib–atezolizumab potential for ICI-treated metastatic NSCLC
“Cabozantinib in combination with atezolizumab has “encouraging” antitumor activity, while cabozantinib alone has “modest” activity, in people who have received prior immune checkpoint inhibitor (ICI) treatment for advanced non-small-cell lung cancer (NSCLC), say trial investigators.”

Safety of Nonsmall Cell Lung Cancer Resection After COVID-19 Pneumonia
“There were no significant differences between postoperative morbidity and mortality among patients with vs without a history of COVID-19 pneumonia who underwent surgical resection for nonsmall cell lung cancer (NSCLC), according to results of a study published in Asian Journal of Surgery.

Liquid biopsy could better predict immunotherapy response in lung cancer patients than tumor biopsy
“Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. Their study was published in the Journal of Experimental & Clinical Cancer Research in June.”

Amivantamab updates confirm NSCLC efficacy for certain patients
“Fresh findings from the phase 1 CHRYSALIS and CHRYSALIS-2 trials have been presented at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA, adding support for the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC).”

Combination extends OS in immunotherapy-resistant advanced non-small cell lung cancer
CHICAGO — “A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.”